Shareholder Approvals
CRISPR Therapeutics and Kaiser Aluminum Shareholders Approve New Incentive Plans and Governance Updates
Anonymous
On June 4, 2026, CRISPR Therapeutics shareholders approved a new 2026 Stock Option and Incentive Plan that rolls over unused shares, expands stock- and cash-based award flexibility, and backs related governance amendments to broaden financial flexibility. The meeting also approved the 2025 financial statements, renewed board and committee leadership, and re-elected the auditor team, indicating widespread support for the company’s current governance and compensation framework. TipRanks’ most recent coverage for CRISPR Therapeutics is a Hold with a $56 price target and a Neutral view from its AI analyst, citing ongoing large losses and negative cash flow despite improving liquidity and cash trends. Also on June 4, 2026, Kaiser Aluminum shareholders approved an increase to its equity compensation plan, adding 395,000 shares to raise the available pool to 1,183,000, along with director elections, advisory approval of executive compensation, and ratification of Deloitte & Touche as auditor. The latest TipRanks view for Kaiser is a Sell with a $142 price target, with an AI-neutral stance pointing to a supportive valuation and guidance outlook tempered by weak historical free-cash-flow conversion and higher balance-sheet leverage.
Key Points
1
CRISPR Therapeutics shareholders approved article-of-association changes that included increases to the “capital band” and approval of “conditional share capital for convertible instruments,” specifically aimed at expanding the company’s flexibility for future financings involving converts.
2
At CRISPR’s meeting, investors approved the 2025 financial statements while also “carried forward the net loss” and “discharged the Board of Directors and Executive Committee from liability,” indicating formal shareholder endorsement of governance and prior-year accounting outcomes.
3
CRISPR Therapeutics re-elected Ernst & Young as both its “Swiss statutory auditor” and its “U.S. registered public accounting firm,” covering both statutory and U.S.-reporting audit roles under the same AGM vote.
4
Kaiser Aluminum shareholders elected “three Class I directors” to terms expiring in 2029, a specific board-refresh detail beyond the summary’s general description of director re-elections.
5
Kaiser Aluminum investors approved, on an “advisory basis,” the compensation of “named executive officers,” and also ratified Deloitte & Touche LLP as the independent auditor specifically for “2026.”
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
7
Reach
17
A
AnonymousAuthor
